News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

FDA Advisory Panel to Review Medtronic, Inc. (MDT) (Jobs)'s Endeavor Drug Eluting Stent in October


8/21/2007 10:31:09 PM

MINNEAPOLIS--(BUSINESS WIRE)--Medtronic, Inc. (NYSE:MDT) announced it has been informed by the U.S. Food and Drug Administration (FDA) that an Advisory Panel will review the Premarket Approval (PMA) application for the Endeavor® Drug Eluting Coronary Stent in October. The FDA will announce the date and the complete agenda four to six weeks prior to the meeting in accordance with their normal communications regarding public panel meetings.

Read at BioSpace.com
Read at Reuters


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES